<DOC>
	<DOCNO>NCT00557778</DOCNO>
	<brief_summary>Evaluate benefit ( rate adherence treatment ) , base LDL-C reduction group expose program reinforcement orientation aim patient , compare control group , previous use rosuvastatin .</brief_summary>
	<brief_title>Education Awareness Program Targeting Assessment Adherence Treatment Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Subjects eligible treatment dyslipidemia statins accord current guideline NCEP ATPIII IV Brazilian Guidelines Dyslipidemia Atherosclerosis Prevention . Patients previous use rosuvastatin , least , 15 day , long than12 month prior inclusion study . Pregnancy childbearing History severe hypersensitivity ( include myopathy ) HMGCoA reductase inhibitor . Subjects indication use cyclosporine association lipid lower drug . Subjects underlying disease may influence lipid level ( i.e . uncontrolled hypothyroidism define Thyroid stimulate hormone ( TSH ) &gt; 1.5 time upper level normality ( ULN ) Visit 1 , AIDS , transplant subject , etc ) . History drug alcohol abuse . Current active liver disease hepatic failure elevation ALT &gt; 3 time ULN . Elevation CPK &gt; 3 time ULN . Elevation seric creatinine &gt; 2,0 mg / dL . History malignancy last 5 year , except basal cell squamous cell carcinoma skin ( woman history Cervical dysplasia must include , unless t3 clear consecutive Papanicolaou ( Pap ) smear , entry study ) . Any known clinical condition , opinion investigator , may compromise subject 's safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>prevention</keyword>
	<keyword>dyslipidemia</keyword>
</DOC>